NetworkNewsBreaks – Cybin Inc. (NYSE American: C
Post# of 341
(Total Views: 184)
Posted On: 09/14/2022 4:49:17 PM
NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S. Food and Drug Administration for its phase 1/2a first in-human clinical trial evaluating CYB003. This milestone achievement marks the industry’s first-ever novel psilocybin analog to enter clinical development; the company has started recruiting patients and expects to provide an interim pharmacokinetic and safety readout later this year,” a recent article reads. “We are extremely pleased to advance CYB003 into clinical development so quickly,” Cybin CEO Doug Drysdale is quoted as saying. “This phase 1/2a trial represents the first time that a psilocybin analog will be evaluated in humans for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering from mental health conditions.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S. Food and Drug Administration for its phase 1/2a first in-human clinical trial evaluating CYB003. This milestone achievement marks the industry’s first-ever novel psilocybin analog to enter clinical development; the company has started recruiting patients and expects to provide an interim pharmacokinetic and safety readout later this year,” a recent article reads. “We are extremely pleased to advance CYB003 into clinical development so quickly,” Cybin CEO Doug Drysdale is quoted as saying. “This phase 1/2a trial represents the first time that a psilocybin analog will be evaluated in humans for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering from mental health conditions.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼